The Advanced Prostate Cancer Pipeline: A Continuum
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Drug development in advanced prostate cancer typically moves along a continuum, first targeting either castration-resistant (hormone-refractory) patients who have already taken the first-line chemotherapy docetaxel or the larger population of those who are chemotherapy-naïve after failing medical and surgical castration. Drugs that can reach into the hormone-sensitive prostate cancer population would reach even more patients. Below are selected drugs in late-stage development for advanced prostate cancer and their progress in the various indications.
You may also be interested in...
US FDA 2020 Novel Approval Count Rises To 53 At CDER, Plus 5 New CBER Biologics
FDA reviewers stuck to established assessment practices during the coronavirus crisis and produced one of the agency’s largest yearly novel approval counts ever.
Spironolactone TOPCAT Regional Analysis Falls Short At US FDA AdComm, But Hospitalizations Drive Vote
A new indication for the generic diuretic in heart failure with preserved ejection fraction gets an 8-4 vote, with one abstention, despite troubles an analysis that tries to revive the TOPCAT trial with an analysis excluding Eastern European sites – or about half the participants.
Keeping Track: Myovant, Almirall, MacroGenics Nab Novel Approvals; Novartis’ Inclisiran Delayed
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: